Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial Evaluating the Safety and Tolerability of NanoDoce® Intratumoral Injection in Subjects With Localized Renal Cell Carcinoma

NCT04260360 is registered in ClinicalTrials.gov with NanOlogy, LLC as lead sponsor.

NCT NCT04260360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial Evaluating the Safety and Tolerability of NanoDoce® Intratumoral Injection in Subjects With Localized Renal Cell Carcinoma
Lead sponsor
NanOlogy, LLC
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2020
Completion date
October 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of kidney, adenocarcinoma, renal, kidney cancer, renal cell cancer, renal cell carcinoma